Evidence map›Paper›PMID 28569217›Full record

ReviewCardiovascular diabetology2017

Platelets, diabetes and myocardial ischemia/reperfusion injury.

Isabella Russo, Claudia Penna, Tiziana Musso, Jasmin Popara, Giuseppe Alloatti, Franco Cavalot, Pasquale Pagliaro

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiovascular diabetology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Platelets and Cardioprotection: The Role of Nitric Oxide and Carbon Oxide.International journal of molecular sciences · 2023
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Isabella RussoDepartment of Clinical and Biological Sciences, University of Turin, 10043, Orbassano, TO, Italy.
Claudia PennaDepartment of Clinical and Biological Sciences, University of Turin, 10043, Orbassano, TO, Italy.
Tiziana MussoDepartment of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.
Jasmin PoparaDepartment of Clinical and Biological Sciences, University of Turin, 10043, Orbassano, TO, Italy.
Giuseppe AlloattiDepartment of Life Sciences and Systems Biology, University of Turin, Turin, Italy.
Franco CavalotInternal Medicine and Metabolic Disease Unit, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy.
Pasquale PagliaroDepartment of Clinical and Biological Sciences, University of Turin, 10043, Orbassano, TO, Italy. Pasquale.Pagliaro@unito.it.ORCID 0000-0002-4386-1383
University of Turin · ITOspedale San Luigi Gonzaga · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and highly interconnected. A complex and entangled interaction is also emerging between platelet function, antiplatelet drugs, coronary diseases and ischemia/reperfusion injury, especially in diabetic conditions. Here we briefly summarize features of antiplatelet therapy in type 2 diabetes (T2DM). We also treat the influence of T2DM on ischemia/reperfusion injury and how anti-platelet therapies affect post-ischemic myocardial damage through pleiotropic properties not related to their anti-aggregating effects. miRNA-based signature associated with T2DM and its cardiovascular disease complications are also briefly considered. Influence of anti-platelet therapies and different effects of healthy and diabetic platelets on ischemia/reperfusion injury need to be further clarified in order to enhance patient benefits from antiplatelet therapy and revascularization. Here we provide insight on the difficulty to reduce the cardiovascular risk in diabetic patients and report novel information on the cardioprotective role of widely used anti-aggregant drugs.

Indexed as

Ischemic Preconditioning, MyocardialAnimalsAspirinBlood PlateletsDiabetes Mellitus, Type 2Drug ResistanceHumansMicroRNAsMyocardial Reperfusion InjuryMyocardiumPlatelet Aggregation InhibitorsRisk FactorsSignal TransductionTreatment OutcomeAspirinMicroRNAsPlatelet Aggregation InhibitorsAntiplatelet therapyAspirinCardioprotectionType 2 diabetes

Identifiers

PMID28569217
PMCPMC5452354
OpenAlexW2618618444

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.